Navigation Links
Quest for better treatment for effects of menopause
Date:5/28/2008

This release is available in Spanish.

During menopause, lack of oestrogens increases the risk of suffering cardiovascular diseases. For her doctoral thesis, University of the Basque Country researcher, Ainhoa Ruiz del Agua, studied the effects of substitute treatments and the genetic factors influencing the response to these therapies.

Menopause is a natural period in the ageing process of a woman. On ceasing the ovary function, the body gradually stops producing eggs and female sex hormones (amongst these being oestrogen and progesterone), responsible for regulating the menstrual cycle. Lack of oestrogens increases the risk of very important diseases with respect to premenopause, amongst these being osteoporosis and illnesses related to the cardiovascular system. Amongst these heart diseases atherosclerosis is the most important, being an illness characterised by the presence of plaques full of lipids (fats) along the walls of the arteries, and which restricts the blood flow, causing high blood pressure. If these plaques break, the result is a thrombosis that can block the artery, causing, amongst other things, heart attack.

To slow down the natural drop in oestrogen level and thus prevent associated problems, substitutive hormonal therapies are prescribed during the menopause, either orally or subcutaneously (with patches), as well as by treatments based on substances that modulate the oestrogen receptor, amongst these being raloxifene. However, the effects of these therapies are disputed, given that there are no definitive conclusions about their usefulness: research carried out to date shows their efficacy in preventing osteoporosis, but it has not been clarified if they are capable of reducing the risk of contracting heart disease. Moreover, the response amongst different women to the same treatment can vary according to environmental factors, population, diet and, of course, as a function of genetic factors.

Ms Ainhoa Ruiz del Aguas PhD thesis addressed these questions when she recently defended it at the University of the Basque Country (UPV/EHU): Oxidative stress biomarkers during postmenopause: effect of substitutive treatments. Dr Ruiz del Agua is a biochemistry graduate who is currently working as a researcher contracted by the Department of Physiology in the Faculty of Medicine and Odontology of the UPV/EHU. Her work was led by Ms Mara Begoa Ruiz Larrea and Mr Jos Ignacio Ruiz Sanz.

Treatment with diverse effects

The principal aim of the research is to determine the effect of substitutive treatments normally administered during postmenopause. Moreover, it aims to define the genetic markers that condition the response to each of the treatments. To this end, Doctor Ruiz del Agua analysed the response by a group of women from Bizkaia to two treatments: on the one hand, to raloxifene and, on the other, to a substitutive hormonal treatment combining estradiol (a type of oestrogen) and progesterone (another female sex hormone).

The conclusions of Doctor Ruiz del Aguas thesis point to raloxifene, while increasing the antioxidant activity of an enzyme known as arilesterase, which is beneficial, has a neutral effect on the cardiovascular system, given that it does not modifiy other cardiovascular risk markers, nor the characteristics of LDL (bad cholesterol) particles.

As regards combined hormonal therapy, Ruiz del Agua points to two main conclusions: it reduces one of the cardiovascular risk markers studied, which is beneficial, but it also reduces antioxidant activity of the serum, which means an adverse effect on the endothelial function (which avoids blood clots forming) and on the balance necessary between oxidant and antioxidant substances.

Genetic factors determining response to treatment

On the one hand, Doctor Ruiz del Agua states that the response to the treatments studied depends on the genetic burden of each patient, this response being favourable or otherwise, depending on the genetic variables carried by the women for the genes analysed.

In the case of hormonal therapies, carriers of the GG genotype (a combination highly frequent in the mpo gene) undergo a drop in the antioxidant activity of the serum, which means, in this sense, a favourable response to the treatment. In the case of raloxifene, only those women who, because of their genetic burden, are disfavoured for the antioxidant activity of arilesterase, gain benefit thanks to the treatment.

In short, this PhD presented at the UPV/EHU shows that certain aspects of treatments employed in postmenopausic women can be approached from an analysis of genetic polymorphisms, a fact which will contribute to the design of more personalised therapies for their application in postmenopause.


'/>"/>

Contact: Alaitz Ochoa de Eribe
alaitzo@elhuyar.com
34-688-673-679
Elhuyar Fundazioa
Source:Eurekalert

Related biology news :

1. Conquest of land began in shark genome
2. UNC study questions FDA genetic-screening guidelines for cancer drug
3. TAU scientists probe deep questions aboard EcoOceans environmental research ship
4. New research on structure of bones raises questions for treatment of osteoporosis
5. Sticky questions tackled in gecko research
6. Computer-based tool aids research, helps thwart questionable publication practices
7. UA-led research team awarded $50 million to solve plant biologys grand challenge questions
8. Cold Spring Harbor Laboratory to play central role addressing key questions in plant biology
9. Simple screening questionnaire for kidney disease outperforms current clinical practice guidelines
10. A fossilized giant rhino bone questions the isolation of Anatolia, 25 million years ago
11. Answer to troublesome question of why some genetic assoc. studies have failed replication attempts
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:4/18/2017)... 18, 2017  Socionext Inc., a global expert in SoC-based imaging ... server, the M820, which features the company,s hybrid codec technology. A ... Tera Probe, Inc., will be showcased during the upcoming Medtec Japan ... at the Las Vegas Convention Center April ... Click here for ...
(Date:4/13/2017)... , April 13, 2017 According to a new ... Authentication, Identity Analytics, Identity Administration, and Authorization), Service, Authentication Type, Deployment Mode, ... IAM Market is expected to grow from USD 14.30 Billion in 2017 ... (CAGR) of 17.3%. ... MarketsandMarkets Logo ...
(Date:4/11/2017)... 2017 No two people are believed ... New York University Tandon School of Engineering and ... that partial similarities between prints are common enough ... phones and other electronic devices can be more ... lies in the fact that fingerprint-based authentication systems ...
Breaking Biology News(10 mins):
(Date:9/19/2017)... ... September 19, 2017 , ... A best-selling author and an ... “Grit” author Angela Duckworth and her team at Character Lab have joined Philadelphia’s ... international law firm with decades of experience supporting high-growth companies in the technology ...
(Date:9/19/2017)... ... September 19, 2017 , ... One of the biggest ... eliminated, said Lyle Probst, President, CEO and Founder of ExcitePCR ™. ... pathogen detection solutions, Probst said, “Sample preparation takes place inside our FireflyDX systems, ...
(Date:9/19/2017)... , ... September 19, 2017 , ... ... today announced a partnership with Cytena GmbH to launch the CloneSelect™ Single-Cell Printer™ ... image analysis to isolate single cells and provide visual documentation of monoclonality for ...
(Date:9/18/2017)... ... September 18, 2017 , ... ... to produce biochar, briquettes, and torrefied wood is the topic of a ... To characterize the potential economic viability of transportable biomass conversion facilities for producing ...
Breaking Biology Technology: